Mustafa Özdoğan, MD· @ozdogan_md · X·· 16 hours agoScore70
Body · original
STATISTICALLY POSITIVE. CLINICALLY THIN.
KEYNOTE-B49: pembrolizumab + chemo delivered just +0.7 months median PFS in PD-L1 CPS≥1 HR+/HER2− advanced breast cancer with no OS benefit.
Significance ≠ meaningful benefit.
@hoperugo #ESMO26
106 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
LBA51matched by Proffered paper 2: Breast cancer, early and advanced stage
Results from KEYNOTE-B49: A phase 3, randomized, double-blind study of pembrolizumab (pembro) vs placebo (pbo) plus chemotherapy (CT) in participants (pts) with HR+/HER2− advanced breast cancer (ABC)
https://esmocongress.esmo.orgSource: Mustafa Özdoğan, MD · x.com